Gencurix Inc. (KOSDAQ:229000)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,740.00
-170.00 (-4.35%)
Mar 9, 2026, 3:30 PM KST
104.93%
Market Cap 87.62B
Revenue (ttm) 3.39B
Net Income (ttm) -12.55B
Shares Out 23.43M
EPS (ttm) -877.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,494,477
Average Volume 7,301,867
Open 3,535.00
Previous Close 3,910.00
Day's Range 3,315.00 - 4,500.00
52-Week Range 1,385.00 - 7,320.00
Beta 1.69
RSI 55.81
Earnings Date Mar 20, 2026

About Gencurix

Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was fo... [Read more]

Industry Medical - Specialties
Sector Healthcare
Founded 2011
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 229000
Full Company Profile

Financial Performance

In 2023, Gencurix's revenue was 2.60 billion, an increase of 1.60% compared to the previous year's 2.56 billion. Losses were -19.26 billion, -21.70% less than in 2022.

Financial Statements

News

There is no news available yet.